Filing Flows › ADC Therapeutics SA (ADCT) › Q1 2026 › vs Q4 2025
ADC Therapeutics SA (ADCT) Q1 2026 vs Q4 2025 (quarter over quarter)
ADC Therapeutics SA's revenue fell $2.2M (-10%) from $23.1M in Q4 2025 to $20.9M in Q1 2026. The biggest changes: Product revenues, net −$2.3M (-10%); Royalties +$72K (+10%).
ADC Therapeutics SA, Q1 2026: revenue $20.9M (-10% year over year), operating margin -121.1%, net loss $33.0M, operating cash flow −$29.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $20.0M | $22.3M | −$2.3M | -10% |
| Royalties | $818K | $746K | $72K | +10% |
| Revenue | $20.9M | $23.1M | −$2.2M | -10% |
| Net loss | $33.0M | $6.4M | $26.6M | +414% |
| Costs & expenses | $53.8M | $41.0M | $12.8M | +31% |
| Operating costs | $46.1M | $41.0M | $5.1M | +12% |
| Interest & other, net | $7.7M | −$11.1M | $18.8M | — |
| Research & development | $19.9M | $18.2M | $1.7M | +9% |
| Sales & marketing | $12.7M | $12.0M | $722K | +6% |
| General & admin | $9.9M | $9.5M | $440K | +5% |
| Other operating costs | $3.6M | $1.4M | $2.3M | +168% |
| Operating cash sources | $33.0M | $6.4M | $26.6M | +414% |
| Share-based compensation | $2.4M | $673K | $1.8M | +263% |
| Working capital & other | $816K | −$25.4M | $26.2M | — |
| Cash used in operations | $29.7M | $31.1M | −$1.4M | -5% |
| Net loss absorbed | $33.0M | $6.4M | $26.6M | +414% |
Questions
How much did ADC Therapeutics SA's revenue grow quarter over quarter in Q1 2026?
ADC Therapeutics SA's revenue fell $2.2M (-10%) from $23.1M in Q4 2025 to $20.9M in Q1 2026.
What drove ADC Therapeutics SA's revenue change in Q1 2026?
Product revenues, net −$2.3M (-10%); Royalties +$72K (+10%).